1000980-71-1

Basic information

• Product Name: ((4R,6R)-6-(2-chloro-6-(3-iodobenzylamino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofu[3,4-d][1,3]dioxol-4-yl)methanol
• CAS NO: 1000980-71-1
• Molecular Weight: 557.775
• Mol File: 1000980-71-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 642.5±65.0 °C(Predicted)
• Density: 1.93±0.1 g/cm3(Predicted)
• CAS DataBase Reference: ((4R,6R)-6-(2-chloro-6-(3-iodobenzylamino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofu[3,4-d][1,3]dioxol-4-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: ((4R,6R)-6-(2-chloro-6-(3-iodobenzylamino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofu[3,4-d][1,3]dioxol-4-yl)methanol(1000980-71-1)
• EPA Substance Registry System: ((4R,6R)-6-(2-chloro-6-(3-iodobenzylamino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofu[3,4-d][1,3]dioxol-4-yl)methanol(1000980-71-1)

Safety Data

• Hazardous Substances Data: 1000980-71-1(Hazardous Substances Data)

Usage

General Description

The chemical compound "((4R,6R)-6-(2-chloro-6-(3-iodobenzylamino)-9H-purin-9-yl)-2,2-dimethyltetrahydrofu[3,4-d][1,3]dioxol-4-yl)methanol" is a complex organic molecule composed of a purine ring, a chloro- and iodobenzylamino-substituted group, and a tetrahydrofuran-dimethyl group. The compound also contains a methanol functional group. This chemical is likely to have important pharmacological or biological properties, given its complex structure and the incorporation of a purine moiety, which is a key component of DNA and RNA. It may also have potential applications in medicinal chemistry or drug development due to its unique structure and potential interactions with biological targets. Additionally, further research is needed to fully understand the properties and potential uses of this compound.

Upstream product

• 5451-40-1 2,6-dichloro-7H-purine 
• 339091-08-6 (2R,5R)-2-(benzoyloxymethyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl dibenzoate 
• 77-76-9 2,2-dimethoxy-propane 
• 163152-42-9 2-chloro-N⁶-(3-iodobenzyl)-9-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)adenine 
• 15373-23-6 (2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl dibenzoate 
• 6974-32-9 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose 
• 163152-31-6 MRS 542 
• 5451-40-1 2,6 dichloropurine 

Relevant articles and documents

COLORING COMPOSITION, CURED FILM, COLOR FILTER, METHOD FOR PRODUCING COLOR FILTER, SOLID STATE IMAGE SENSOR, IMAGE DISPLAY DEVICE AND COMPOUND

PROBLEM TO BE SOLVED: To provide a coloring composition that makes it possible to produce a cured film having excellent heat resistance and solvent resistance, and high contrast, and a cured film, a color filter, a method for producing a color filter, a solid state image sensor, an image display device and a colorable compound using the coloring composition. SOLUTION: A coloring composition comprises a compound represented by the formula and a resin [R1 and R2 independently represent a substituent; R3-R6 independently represent H or a substituent; R7-R11 independently represent a substituent; at least one of R1-R11 is a group comprising a carboxyl group; n1-n4 independently represent an integer of 0-4; n5 is an integer of 0-6; X is an anion]. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

Novel Adenine Derivatives and the Use Thereof

The present invention relates to a novel adenine derivative and a pharmaceutical use thereof and, more specifically, to a novel adenine derivative having a structure of chemical formula 1 or a pharmaceutically acceptable salt thereof, and to a composition containing the same for preventing or treating degenerative brain disease. The novel adenine derivative and the pharmaceutically acceptable salt thereof according to the present invention are adenosine A3 receptor agonists, and have an action of inhibiting the migration (or infiltration) of inflammatory cells (microglia, macrophages, neutrophils, etc.), to disease areas and the activities thereof. In addition, the adenine derivative according to the present invention was verified to suppress and treat brain injury more remarkably when compared with the known adenosine A3 receptor agonists in a cerebral ischemia experimental model, exhibit a significant effect by drug administration 10 hours after cerebral infarction, and allow long-term survival in spite of brain injury due to cerebral ischemia, and thus can be useful as an agent for treating and preventing degenerative brain disease including stroke.(AA,BB,CC,DD) Chemical formula 5COPYRIGHT KIPO 2015